Roche Q1 Report 2024
- Group sales grew by 2% at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales decline
- Due to the appreciation of the Swiss franc against most currencies, sales were 6% lower when reported in CHF
- Pharmaceuticals Division base business grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A). Divisional sales growth was 2%, reflecting the impact of the expected decline in sales of the COVID-19 medicine Ronapreve
- Strong Pharma (+7% at CER) and Diagnostics (+8% at CER) base business growth
- COVID-19 sales decreased by CHF -0.7bn and LOE1 impact was CHF -0.4bn, both in line with guidance
- Pharma regulatory: US approval for Xolair in food allergy and Alecensa in adjuvant ALK+ NSCLC, US filing for inavolisib in 1L PIK3CA-mut HR+ BC
- Pharma readouts: Positive Ph III (STARGLO) Columvi in 2L+ DLBCL, positive Ph II (KARDIA-2) zilebesiran in hypertension
- Diagnostics regulatory: US approval for molecular blood screening for malaria, FDA BDD for pTau217 AD rule-in blood test
